We’d like to introduce you to the fellow above, whose name is Jae. When asked what area of study she specializes in, she only ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

Stealth BioTherapeutics had expected the FDA to respond on Tuesday to its marketing application for elamipretide to treat ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

Funding for a landmark health study, the Women's Health Initiative, was cut then reportedly restored, but researchers are ...

There is common ground. Most adults favor: Preventing chronic diseases (Republicans 86%, Democrats 91%) Protecting against ...

If the law is struck down or any ambiguity left surrounding its validity, coverage of and access to preventive care like PrEP ...

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

As of last week, Chris Klomp is in charge of the Center for Medicare. Unlike predecessors, he’s not a policy wonk. Klomp was ...

With a May 24 deadline looming, Kennedy's MAHA commission has held just one full meeting on its goal of reducing childhood ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

Some telehealth companies that offered compounded GLP-1s have disappeared altogether. Others are pursuing strategies that ...